Effects of Low-Dose Prednisolone on Hepatic and Peripheral Insulin Sensitivity, Insulin Secretion, and Abdominal Adiposity in Patients With Inflammatory Rheumatologic Disease

Carolyn J. Petersons; Brenda L. Mangelsdorf; Arthur B. Jenkins; Anne Poljak; Malcolm D. Smith; Jerry R. Greenfield; Campbell H. Thompson; Morton G. Burt

doi:10.2337/dc12-2617

Original Research

Effects of Low-Dose Prednisolone on Hepatic and Peripheral Insulin Sensitivity, Insulin Secretion, and Abdominal Adiposity in Patients With Inflammatory Rheumatologic Disease

Carolyn J. Petersons, MBBS¹,² ⇑,
Brenda L. Mangelsdorf, RN²,
Arthur B. Jenkins, PHD³,⁴,
Anne Poljak, PHD⁵,
Malcolm D. Smith, PHD¹,⁶,
Jerry R. Greenfield, PHD³,⁷,
Campbell H. Thompson, PHD¹,⁸ and
Morton G. Burt, PHD¹,²

¹Faculty of Health Sciences, Flinders University, Adelaide, Australia
²Southern Adelaide Diabetes and Endocrine Services, Repatriation General Hospital, Adelaide, Australia
³Diabetes and Obesity Research Program, Garvan Institute of Medical Research, Sydney, Australia
⁴School of Health Sciences, University of Wollongong, Wollongong, Australia
⁵Bioanalytical Mass Spectrometry Facility and School of Medical Sciences, University of New South Wales, Sydney, Australia
⁶Department of Rheumatology, Repatriation General Hospital, Adelaide, Australia
⁷Department of Endocrinology, St. Vincent’s Hospital, Sydney, Australia
⁸Discipline of Medicine, University of Adelaide, Adelaide, Australia

Corresponding author: Carolyn J. Petersons, carolynpetersons{at}yahoo.com.au

Diabetes Care 2013 Sep; 36(9): 2822-2829. https://doi.org/10.2337/dc12-2617

Article Figures & Tables

Figures

Tables

Download figure
Open in new tab
Download powerpoint
Figure 1
Endogenous glucose production in non-GC users before and after administration of low-dose prednisolone for 7–10 days and in long-term GC users. Data are mean ± SD. B, basal EGP; LDC, low-dose clamp; HDC, high-dose clamp. *P = 0.05 compared with basal EGP in non-GC users at baseline. #P < 0.05 compared with percentage of insulin suppression of EGP in non-GC users at baseline.
Download figure
Open in new tab
Download powerpoint
Figure 2
A: Mean glucose infusion rate at steady state during high-dose clamp study corrected for FFM and for serum insulin concentration (M/I) in non-GC users before and after administration of low-dose prednisolone for 7–10 days and in long-term GC users. Data are mean ± SD. *P < 0.05 compared with non-GC users at baseline. B: Rate of oxidative (white bars) and nonoxidative (black bars) Rd at steady state during high-dose clamp study in non-GC users before and after administration of low-dose prednisolone for 7–10 days and in long-term GC users. Data are mean ± SD. *P < 0.05 compared with total Rd in non-GC users at baseline. #P < 0.05 compared with percentage of nonoxidative glucose disposal in non-GC users at baseline.
Download figure
Open in new tab
Download powerpoint
Figure 3
A: First-phase insulin secretion (area under the curve [AUC] insulin:AUC glucose) in non-GC users before and after administration of low-dose prednisolone for 7–10 days and in long-term GC users. Data are mean ± SD. *P < 0.05 compared with non-GC users at baseline. B: Second-phase insulin secretion (AUC insulin:AUC glucose) in non-GC users before and after administration of low-dose prednisolone for 7–10 days and in long-term GC users. Data are mean ± SD. *P < 0.05 compared with non-GC users at baseline.